Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237509 | 0.90 | ALOX5 (0.41) | ALOX5PLA2G2AMAPTALDH1A1KDM4E | |
| SCHEMBL5240856 | 0.85 | ALOX5 (0.47) | ALOX5PLA2G2A | |
| SCHEMBL5238204 | 0.81 | SMN1; SMN2 (0.52) | ALOX5SRCPLA2G2AKMT2AMAPT | |
| SCHEMBL5950819 | 0.81 | SRC (0.51) | SRCMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL5240891 | 0.77 | OXER1 (0.43) | ALOX5PLA2G2AALDH1A1GAAALOX15 | |
| SCHEMBL5237757 | 0.75 | CA12 (0.39) | ALOX5SRCMEN1KMT2AMAPT | |
| SCHEMBL31563182 | 0.74 | ATM (0.42) | ALOX5MEN1KMT2AMAPTPKM | |
| SCHEMBL9095202 | 0.74 | ALOX5 (0.53) | ALOX5MEN1KMT2AMAPTPKM | |
| SCHEMBL24482982 | 0.71 | ALDH1A1 (0.43) | ALOX5SRCPLA2G2AMEN1KMT2A | |
| SCHEMBL9093397 | 0.71 | ALOX5 (0.53) | ALOX5MEN1KMT2AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR2C, HTR4, HTR3C | ALOX5 367/4885SRC 1991/4885PLA2G2A 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.